Accelerate Diagnostics Inc (AXDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Accelerate Diagnostics Inc (AXDX) has a cash flow conversion efficiency ratio of 0.090x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.07 Million) by net assets ($-56.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Accelerate Diagnostics Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Accelerate Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Accelerate Diagnostics Inc (AXDX) financial obligations for a breakdown of total debt and financial obligations.
Accelerate Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Accelerate Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Microlise Group PLC
LSE:SAAS
|
0.055x |
|
Migo Opportunities Trust PLC
LSE:MIGO
|
-0.009x |
|
OSX Brasil S.A
SA:OSXB3
|
-0.002x |
|
Hansard Global Plc
LSE:HSD
|
0.442x |
|
Arkle Resources PLC
STU:48O
|
-0.027x |
|
IG Design Group plc
LSE:IGR
|
-0.368x |
|
4BASEBIO UK SOCIETAS
LSE:4BB
|
-0.402x |
|
First Tin PLC
LSE:1SN
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Accelerate Diagnostics Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Accelerate Diagnostics Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Accelerate Diagnostics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-56.04 Million | $-24.19 Million | 0.432x | -78.64% |
| 2023-12-31 | $-19.89 Million | $-40.20 Million | 2.021x | -7.65% |
| 2022-12-31 | $-22.26 Million | $-48.73 Million | 2.189x | +62.20% |
| 2021-12-31 | $-35.07 Million | $-47.32 Million | 1.349x | +68.19% |
| 2020-12-31 | $-62.81 Million | $-50.39 Million | 0.802x | -90.86% |
| 2019-12-31 | $-7.38 Million | $-64.79 Million | 8.781x | +843.55% |
| 2018-12-31 | $57.38 Million | $-67.76 Million | -1.181x | -154.04% |
| 2017-12-31 | $119.92 Million | $-55.75 Million | -0.465x | +32.27% |
| 2016-12-31 | $77.82 Million | $-53.41 Million | -0.686x | -159.91% |
| 2015-12-31 | $133.02 Million | $-35.13 Million | -0.264x | +7.23% |
| 2014-12-31 | $65.99 Million | $-18.79 Million | -0.285x | -21.23% |
| 2013-12-31 | $41.52 Million | $-9.75 Million | -0.235x | -326.92% |
| 2012-12-31 | $14.84 Million | $-816.00K | -0.055x | -159.06% |
| 2011-12-31 | $4.82 Million | $448.48K | 0.093x | +157.91% |
| 2010-12-31 | $4.91 Million | $-789.60K | -0.161x | -177.56% |
| 2009-12-31 | $3.89 Million | $-225.66K | -0.058x | +73.47% |
| 2008-12-31 | $4.41 Million | $-963.73K | -0.218x | +30.60% |
| 2007-12-31 | $4.88 Million | $-1.54 Million | -0.315x | +19.70% |
| 2006-12-31 | $6.74 Million | $-2.64 Million | -0.392x | -136.86% |
| 2005-12-31 | $9.67 Million | $-1.60 Million | -0.165x | -59.77% |
| 2004-12-31 | $11.74 Million | $-1.22 Million | -0.104x | -972.01% |
| 2003-12-31 | $12.73 Million | $151.16K | 0.012x | +124.54% |
| 2002-12-31 | $13.74 Million | $-665.16K | -0.048x | -629.80% |
| 2001-12-31 | $9.61 Million | $-63.73K | -0.007x | -118.19% |
| 2000-12-31 | $11.26 Million | $410.61K | 0.036x | -57.03% |
| 1999-12-31 | $12.24 Million | $1.04 Million | 0.085x | -71.36% |
| 1998-12-31 | $12.36 Million | $3.66 Million | 0.296x | +202.88% |
| 1997-12-31 | $9.20 Million | $900.00K | 0.098x | -83.10% |
| 1996-12-31 | $1.90 Million | $1.10 Million | 0.579x | -- |
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more